About attovia therapeutics inc - ATTO
Attovia Therapeutics, Inc. is a biopharmaceutical company developing precision multispecific biologics to address immune-mediated and inflammatory diseases, including dermatology conditions such as atopic dermatitis and chronic pruritus, and gastroenterology disorders like inflammatory bowel disease. The company is based in San Carlos, CA. The company utilizes its proprietary Attobody™ platform to design novel multispecific molecules that inhibit multiple disease-driving pathways. Key pipeline candidates include ATTO-1310 (anti-IL31) and ATTO-3712 (anti-IL31 x IL13), both in phase 1 clinical trials for chronic pruritus and inflammatory skin disease, and ATTO-1091, a trispecific molecule in IND-enabling stages for inflammatory bowel disease. The company was founded in 2022 by Petter Veiby, Tao Fu, Zaneta Odrowaz. Tao Fu has been the CEO of the company since 2022.
ATTO At a Glance
Attovia Therapeutics, Inc.
1091 Industrial Road
San Carlos, California 94070
| Phone | 1-510-399-5001 | Revenue | 1.35M | |
| Industry | Biotechnology | Net Income | -60,898,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ATTO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ATTO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.011 |
ATTO Liquidity
| Current Ratio | 14.20 |
| Quick Ratio | 14.20 |
| Cash Ratio | 13.834 |
ATTO Profitability
| Gross Margin | 40.444 |
| Operating Margin | -4,974.741 |
| Pretax Margin | -4,490.889 |
| Net Margin | -4,510.963 |
| Return on Assets | -50.203 |
| Return on Equity | -57.203 |
| Return on Total Capital | -39.024 |
| Return on Invested Capital | -56.32 |
ATTO Capital Structure
| Total Debt to Total Equity | 3.49 |
| Total Debt to Total Capital | 3.372 |
| Total Debt to Total Assets | 3.172 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 2.141 |